Triage of women with minor abnormal cervical cytology: Meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types

Cancer Cytopathology

Volumn 121, Issue 12, 2013, Pages 675-687

  Verdoodt, Freija ^a   Szarewski, Anne ^b   Halfon, Philippe ^c   Cuschieri, Kate ^d   Arbyn, Marc ^a  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c Laboratory Alphabio   (France)

^d ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Atypical squamous cells of undetermined significance; Cervical cancer; Cervical intraepithelial neoplasia; Diagnostic accuracy; HPV; Human papillomavirus testing; Low grade squamous intraepithelial lesions; Messenger RNA; Meta analysis; Triage

Indexed keywords

MESSENGER RNA; VIRUS DNA; VIRUS RNA;

COLPOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DNA DETERMINATION; EMERGENCY HEALTH SERVICE; FALSE POSITIVE RESULT; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; META ANALYSIS; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; PRIORITY JOURNAL; PUNCH BIOPSY; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; UTERUS BIOPSY; WART VIRUS; ADULT; ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE; EARLY DIAGNOSIS; FEMALE; GENETICS; HUMAN PAPILLOMAVIRUS TESTING; ISOLATION AND PURIFICATION; LOW-GRADE SQUAMOUS INTRAEPITHELIAL LESIONS; METHODOLOGY; MIDDLE AGED; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; UTERINE CERVIX CANCER; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY; CERVICAL INTRAEPITHELIAL NEOPLASIA; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; UTERINE CERVICAL NEOPLASMS;

ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE; CERVICAL CANCER; CERVICAL INTRAEPITHELIAL NEOPLASIA; DIAGNOSTIC ACCURACY; HPV; HUMAN PAPILLOMAVIRUS TESTING; LOW-GRADE SQUAMOUS INTRAEPITHELIAL LESIONS; MESSENGER RNA; META-ANALYSIS; TRIAGE;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RNA, MESSENGER; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; TRIAGE; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84886749737     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21325     Document Type: Review

References (68)

1. Arbyn M, Castellsague X, de Sanjose S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22:2675-2686.
2. zur Hausen H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Top Microbiol Immunol. 1994;186:131-156.
3. IARC Monograph Working Group. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 90: Human Papillomaviruses. Lyon, France; IARC; 2007:1-670.
4. Laara E, Day NE, Hakama M. Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet. 1987;1:1247-1249.
5. Anttila A, Laara E. Cervix cancer: geographical correlations. In: Sankila R, Demaret E, Hakama M, Lynge E, Shouten LJ, Parkin EM, eds. Evaluation and Monitoring of Screening Programmes. Brussels, Belgium: Europe Against Cancer Programme; 2000: 77-97.
6. Arbyn M, Raifu AO, Weiderpass E, Bray F, Anttila A. Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer. 2009;45:2640-2648.
7. Stoler MH, Schiffman MA. Interobserver reproducibility of cervical cytologic and histologic interpretations. JAMA. 2001;285: 1500-1505.
8. Holowaty P, Miller AB, Rohan T, To T. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst. 1999;91:252-258.
9. Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol. 1998;92:727-735.
10. Arbyn M, Ronco G, Cuzick J, Wentzensen N, Castle PE. How to evaluate emerging technologies in cervical cancer screening? Int J Cancer. 2009;125:2489-2496.
11. Jordan J, Arbyn M, Martin-Hirsch P, et al. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1. Cytopathology. 2008;19:342-354.
12. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 Consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007;197:346-355.
13. Arbyn M, Roelens J, Simoens C, et al. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions [serial online]. Cochrane Database Syst Rev. 2013;(3): CD008054.
14. Arbyn M, Martin-Hirsch P, Buntinx F, Van Ranst M, Paraskevaidis E, Dillner J. Triage of women with equivocal or low-grade cervical cytology results. A meta-analysis of the HPV test positivity rate. J Cell Mol Med. 2009;13:648-659.
15. Lorincz AT. Hybrid capture. Clin Chem. 1998;44:1363-1363.
16. Solomon D, Schiffman MA, Tarone B. Comparison of 3 management strategies for patients with atypical squamous cells of undetermined significance (ASCUS): baseline results from a randomized trial. J Natl Cancer Inst. 2001;93:293-299.
17. Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst. 2004;96:280-293.
18. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 2006;24(suppl 3):S78-S89.
19. Arbyn M, Ronco G, Anttila A, et al. Evidence regarding HPV testing in secondary prevention of cervical cancer. Vaccine. 2012; 30(suppl 5):F88-F99.
20. ASCUS-LSIL Triage Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol. 2003;188:1393-1400.
21. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 2006;110:525-541.
22. Doorbar J, Quint W, Banks L, et al. The biology and life-cycle of human papillomaviruses. Vaccine. 2012;30(suppl 5):F55-F70.
23. Wang-Johanning F, Lu DW, Wang Y, Johnson MR, Johanning GL. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis. Cancer. 2002; 94:2199-2210.
24. Cuschieri KS, Whitley MJ, Cubie HA. Human papillomavirus type specific DNA and RNA persistence-implications for cervical disease progression and monitoring. J Med Virol. 2004;73:65-70.
25. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048-1056.
26. Dockter J, Schroder A, Eaton B, et al. Analytical characterization of the APTIMA HPV assay. J Clin Virol. 2009;45(suppl 1): S39-S47.
27. Narimatsu R, Patterson BK. High-throughput cervical cancer screening using intracellular human papillomavirus E6 and E7 mRNA quantification by flow cytometry. Am J Clin Pathol. 2005; 123:716-723.
28. Coquillard G, Palao B, Patterson BK. Quantification of intracellular HPV E6=E7 mRNA expression increases the specificity and positive predictive value of cervical cancer screening compared to HPV DNA. Gynecol Oncol. 2011;120:89-93.
29. Shen Y, Gong J, He Y, Cheng G, Okunieff P, Li X. Quantivirus HPV E6=E7 RNA 3.0 assay (bDNA) is as sensitive, but less specific than Hybrid Capture 2 test. J Virol Methods. 2012;187: 288-293.
30. Arbyn M, Roelens J, Cuschieri K, et al. The APTIMA HPV assay versus the Hybrid Capture II test in triage of women with ASCUS or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy. Int J Cancer. 2013;132:101-108.
31. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114-2119.
32. The 1988 Bethesda System for reporting cervical=vaginal cytologic diagnoses. National Cancer Institute Workshop. JAMA. 1989;262: 931-934.
33. Evans DM, Hudson EA, Brown CL, et al. Terminology in gynaecological cytopathology: report of the Working Party of the British Society for Clinical Cytology. J Clin Pathol. 1986;39:933-944.
34. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529-536.
35. Harbord RM, Deeks JJ, Egger M, Whiting P, Sterne JA. A unification of models for meta-analysis of diagnostic accuracy studies. Biostatistics. 2007;8:239-251.
36. Harbord RM, Whiting P. Metandi: meta-analysis of diagnostic accuracy using hierarchical logistic regression. Stata J. 2009;9: 211-229.
37. Takwoingi Y, Diagnostic Test Accuracy Working Group. METADAS: an SAS macro for meta-analysis of diagnostic accuracy studies. Available at: http://srdta.cochrane.org/sites/srdta.cochrane.org/files/uploads/ MetaDAS%20Readme%20v1.3%20May%202012.pdf. [Accessed June 10, 2013.]
38. Diagnostic Test Accuracy Working Group. Handbook for Diagnostic Test Accuracy Reviews. Available at: http:==srdta.cochrane. org=handbook-dta-reviews. [Accessed June 10, 2013.]
39. Andersson S, Hansson B, Norman I, et al. Expression of E6=E7 mRNA from "high risk" human papillomavirus in relation to CIN grade, viral load and p16INK4a. Int J Oncol. 2006;29:705-711.
40. Szarewski A, Ambroisine L, Cadman L, et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev. 2008;17: 3033-3043.
41. Halfon P, Benmoura D, Agostini A, et al. Relevance of HPV mRNA detection in a population of ASCUS plus women using the NucliSENS EasyQ HPV assay. J Clin Virol. 2010;47:177-181.
42. Andersson E, Karrberg C, Radberg T, et al. Type-specific HPV E6=E7 mRNA detection by real-time PCR improves identification of cervical neoplasia. J Clin Microbiol. 2011;49:3794-3799.
43. Ratnam S, Coutlee F, Fontaine D, et al. Aptima HPV E6=E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer. J Clin Microbiol. 2011;49:557-564.
44. Szarewski A, Mesher D, Cadman L, et al. A comparison of 7 tests for high grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. J Clin Microbiol. 2012; 50:1867-1873.
45. Molden T, Nygard JF, Kraus I, et al. Predicting CIN21 when detecting HPV mRNA and DNA by PreTect HPV-Proofer and consensus PCR: a 2-year follow-up of women with ASCUS or LSIL Pap smear. Int J Cancer. 2005;114:973-976.
46. Koliopoulos G, Chrelias C, Pappas A, et al. The diagnostic accuracy of 2 methods for E6&7 mRNA detection in women with minor cytological abnormalities. Acta Obstet Gynecol Scand. 2012; 91:794-801.
47. Alaghehbandan R, Fontaine D, Bentley J, et al. Performance of ProExC and PreTect HPV-Proofer E6=E7 mRNA tests in comparison with the hybrid capture 2 HPV DNA test for triaging ASCUS and LSIL cytology [published online ahead of print January 22, 2013]. Diagn Cytopathol. 2013.
48. Sorbye SW, Fismen S, Gutteberg TJ, Mortensen ES. HPV mRNA test in women with minor cervical lesions: experience of the University Hospital of North Norway. J Virol Methods. 2010;169: 219-222.
49. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intra-epithelial or early invasive cervical lesions: a systematic review and meta-analysis of the literature. Lancet. 2006; 367:489-498.
50. Arbyn M, Kyrgiou M, Simoens C, et al. Peri-natal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: a meta-analysis [serial online]. BMJ. 2008;337:a1284.
51. ASCUS-LSIL Triage Study (ALTS) Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized tria. J Natl Cancer Inst. 2000;92:397-402.
52. Ratnam S, Coutlee F, Fontaine D, et al. Clinical performance of the PreTect HPV-Proofer E6=E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer. J Clin Microbiol. 2010;48:2779-2785.
53. Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111:278-285.
54. Nakagawa S, Yoshikawa H, Yasugi T, et al. Ubiquitous presence of E6 and E7 transcripts in human papillomavirus-positive cervical carcinomas regardless of its type. J Med Virol. 2000;62: 251-258.
55. Hovland S, Arbyn M, Lie AK, et al. A comprehensive evaluation of the accuracy of cervical pre-cancer detection methods in a high-risk area in East Congo. Br J Cancer. 2010;102: 957-965.
56. Burger EA, Kornor H, Klemp M, Lauvrak V, Kristiansen IS. HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review. Gynecol Oncol. 2011;120:430-438.
57. Tarkowski TA, Rajeevan MS, Lee DR, Unger ER. Improved detection of viral RNA isolated from liquid-based cytology samples. Mol Diagn. 2001;6:125-130.
58. Pretorius RG, Kim RJ, Belinson JL, Elson P, Qiao YL. Inflation of sensitivity of cervical cancer screening tests secondary to correlated error in colposcopy. J Low Genit Tract Dis. 2006;10:5-9.
59. Roelens J, Reuschenbach M, von Knebel-Doeberitz M, Wentzensen N, Bergeron C, Arbyn M. p16INK4a immunocytochemistry versus HPV testing for triage of women with minor cytological abnormalities: a systematic review and meta-analysis. Cancer Cytopathol. 2012;120:294-307.
60. Sanati S, Huettner P, Ylagan LR. Role of ProExC: a novel immunoperoxidase marker in the evaluation of dysplastic squamous and glandular lesions in cervical specimens. Int J Gynecol Pathol. 2010; 29:79-87.
61. Wentzensen N, Sherman ME, Schiffman M, Wang SS. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-The-science. Gynecol Oncol. 2009;112:293-299.
62. Varnai AD, Bollmann M, Bankfalvi A, et al. Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6=E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: diagnostic and prognostic implications. Oncol Rep. 2008;19:457-465.
63. Benevolo M, Terrenato I, Mottolese M, et al. Diagnostic and prognostic validity of the human papillomavirus E6=E7 mRNA test in cervical cytological samples of HC2-positive patients. Cancer Causes Control. 2011;22:869-875.
64. Boulet GA, Micalessi IM, Horvath CA, Benoy IH, Depuydt CE, Bogers JJ. Nucleic acid sequence-based amplification assay for human papillomavirus mRNA detection and typing: evidence for DNA amplification. J Clin Microbiol. 2010;48:2524-2529.
65. Halfon P, Benmoura D, Agostini A, et al. Stepwise algorithm combining HPV high-risk DNA-based assays and RNA-based assay for high grade CIN in women with abnormal smears referred to colposcopy. Cancer Biomarkers. 2010;7:133-139.
66. Hesselink AT, Heideman DA, Steenbergen RD, et al. Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women. Clin Cancer Res. 2011;17:2459-2465.
67. Rijkaart DC, Heideman DA, Coupe VM, et al. High-risk human papillomavirus (hrHPV) E6=E7 mRNA testing by PreTect HPVProofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology. J Clin Microbiol. 2012;50:2390-2396.
68. Rijkaart DC, Berkhof J, van Kemenade FJ, et al. Evaluation of 14 triage strategies for HPV DNA-positive women in populationbased cervical screening. Int J Cancer. 2012;130:602-610.